Literature DB >> 27029633

Progressive diffuse meningioangiomatosis: Response to bevacizumab treatment.

Shlomit Yust-Katz1, Gregory Fuller2, Suzana Fichman-Horn2, Natalia Michaeli2, Edna Inbar2, Judith Lukman2, Dror Limon2, Israel Steiner2, Tali Siegal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27029633      PMCID： PMC4844238          DOI： 10.1212/WNL.0000000000002610

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Meningioangiomatosis: a rare presentation with progressive cortical blindness.

Authors:  Akshay Shah; Daniel Korya; Brandon T Larsen; Myrka Torres; Kendra Drake; John La Wall
Journal:  Neurology       Date:  2013-07-30       Impact factor: 9.910

2.  Sporadic meningioangiomatosis with and without meningioma: analysis of clinical differences and risk factors for poor seizure outcomes.

Authors:  Chao Zhang; Yao Wang; Xiu Wang; Jian-Guo Zhang; Jing-Jun Li; Wen-Han Hu; Kai Zhang
Journal:  Acta Neurochir (Wien)       Date:  2015-03-11       Impact factor: 2.216

Review 3.  Meningioangiomatosis. A comprehensive analysis of clinical and laboratory features.

Authors:  S Wiebe; D G Munoz; S Smith; D H Lee
Journal:  Brain       Date:  1999-04       Impact factor: 13.501

Review 4.  Meningioangiomatosis in a patient with progressive focal neurological deficit-case report and review of literature.

Authors:  A Abdulazim; M A Samis Zella; M Rapp; K Gierga; K J Langen; H J Steiger; M Sabel
Journal:  Br J Neurosurg       Date:  2012-11-20       Impact factor: 1.596

5.  Sporadic meningioangiomatosis: imaging findings with histopathologic correlations in seven patients.

Authors:  Tae Yeon Jeon; Ji Hye Kim; Yeon-Lim Suh; Soomin Ahn; So-Young Yoo; Hong Eo
Journal:  Neuroradiology       Date:  2013-10-24       Impact factor: 2.804

Review 6.  Update on anti-angiogenic treatment for malignant gliomas.

Authors:  John F de Groot; Jacob J Mandel
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

7.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.